Home Cart Sign in  
Chemical Structure| 1831110-54-3 Chemical Structure| 1831110-54-3

Structure of MS023
CAS No.: 1831110-54-3

Chemical Structure| 1831110-54-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

MS023 is a potent and selective chemical probe for Type I PRMTs with IC50 values of 30, 119, 83, 8, and 8 nM for PRMTs 1,3,4,6,and 8, respectively. MS023 is active in cells.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of MS023

CAS No. :1831110-54-3
Formula : C17H25N3O
M.W : 287.40
SMILES Code : CN(CCN)CC1=CNC=C1C2=CC=C(OC(C)C)C=C2
MDL No. :MFCD29924734
InChI Key :FMTVWAGUJRUAKE-UHFFFAOYSA-N
Pubchem ID :92136227

Safety of MS023

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of MS023

epigenetics

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Hs578-T 1 μM 5 days MS023 treatment did not significantly affect cell growth PMC9337992
MDA-MB-468 1 μM 5 days MS023 treatment induced cell cycle arrest and apoptosis, suppressing tumor growth PMC9337992
HT-29 5 µM 5 days MS023 significantly increased ALP activity and delayed cell proliferation in HT-29 cells. PMC7676271
786-0 5 µM 7 days To validate MS023’s on-target activity, a global downregulation of aDMA species was observed. PMC11413393
RCC243 5 µM 7 days To validate MS023’s on-target activity, a global downregulation of aDMA species was observed. PMC11413393
SMA type II patient-derived fibroblasts 100 nM–10 µM 48 h MS023 treatment dose-dependently increased SMN2 exon 7 inclusion and protein levels. PMC10630883
SMA type II patient-derived fibroblasts 1-10 µM 48 h MS023 treatment increased SMN2 exon 7 inclusion and elevated SMN protein levels up to 1.6-fold. PMC10630883
A549 cells 1 μM 24 h To study the inhibitory effect of C-MS023 on histone arginine asymmetric dimethylation, results showed that C-MS023 had a weak influence on H3R2me2a and H4R3me2a marks at 1 μM, but significantly downregulated these marks after 420 nm light irradiation. PMC11873949
A549 cells 0.1 μM 24 h To study the inhibitory effect of MS023 on histone arginine asymmetric dimethylation, results showed that MS023 significantly reduced the levels of H3R2me2a and H4R3me2a marks. PMC11873949
HCT-116 20 µM 5 days MS023 had minimal effect on ALP activity but significantly reduced cell proliferation in HCT-116 cells. PMC7676271
K562 cells 1 μM 4 days MS023 treatment significantly reduced H3R2me2a modification levels and increased γ-globin expression, partially rescuing the erythroid differentiation defects caused by the GATA1 Leu387fs mutation. PMC11367199

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice CcRCC xenograft models Intraperitoneal injection 80 mg/kg 3 days on/4 days off, for 3 weeks To evaluate the antitumor activity of MS023 in ccRCC xenograft models, significant inhibition of tumor growth was observed. PMC11413393
Mice Myocardial infarction model Intraperitoneal injection 80 mg/kg Every 3 days, starting from 3 days before surgery Pretreatment with MS023 significantly improved cardiac function and reduced fibrosis in Hdc/C0//C0 mice after myocardial infarction PMC9279636
Mice CML mouse model Intraperitoneal injection 80 mg/kg Once daily for 2 weeks MS023 significantly prolonged the survival of CML mice, alleviated splenomegaly, and markedly reduced the leukemia burden and the proportions of LSPCs, with minimal impact on normal hematopoiesis. PMC11791931
Mice MDA-MB-468 xenograft model Intraperitoneal injection 60 mg/kg Once daily for 5 weeks MS023 significantly reduced tumor growth and final tumor weight PMC9337992
Mice SMA mouse model Oral 2 mg/kg Daily, from P0 to endpoint MS023 treatment significantly increased the survival rate of SMA mice and improved disease-associated weight loss. PMC10630883
Nude mice HT-29 xenograft model Intraperitoneal injection 15 mg/kg and 30 mg/kg Twice a week for 19 days MS023 significantly delayed the growth of HT-29 xenograft tumors and reduced tumor cell proliferation. PMC7676271
C57BL6/J mice Wild-type Intraperitoneal injection 80 mg/kg Every other day for one month To evaluate the effect of MS023 on megakaryocyte differentiation and platelet production, results showed that MS023 increased the number of high polyploid megakaryocytes and platelets. PMC9110119

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.48mL

0.70mL

0.35mL

17.40mL

3.48mL

1.74mL

34.79mL

6.96mL

3.48mL

References

 

Historical Records

Categories